Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL
Blood Podcast
00:00
Understanding Neutropenia Risk and Inotuzumab Resistance in B-ALL
This chapter examines a new risk scoring system aimed at identifying patients at high risk for severe prolonged neutropenia following CAR T-cell therapy for B-ALL. It also delves into the resistance mechanisms associated with inotuzumab ozogamicin, specifically the role of the DNTT gene as a potential biomarker for treatment resistance.
Transcript
Play full episode
